

BIOMÉRIEUX

INNOVATING MICROBIOLOGY

VITEK® REVEAL™

FAST AST FOR BLOODSTREAM INFECTIONS.
INTEGRATED & FLEXIBLE SOLUTION.
ACTIONABLE RESULTS.



OPTIMIZE DIAGNOSTICS.
MANAGE SEPSIS.
With our fast, integrated sepsis solution.

PIONEERING DIAGNOSTICS

VITEK® REVEAL™

ACCELERATE TIME TO OPTIMAL THERAPY FOR PATIENTS WITH BLOODSTREAM INFECTIONS

For patients with bloodstream infections (BSIs), early optimal antimicrobial treatment is critical. VITEK REVEAL supports antimicrobial stewardship (AMS) by delivering fast actionable antimicrobial susceptibility testing (AST) results that can help clinicians address both unnecessary and inappropriate treatment.

90% of patients treated with broad-spectrum antibiotics for suspected sepsis do not have resistant pathogens¹

Contributing to an increase of antimicrobial resistance and negatively impacting patient care²

EARLY OPTIMAL ANTIMICROBIAL TREATMENT WITH FAST AST



20% of patients receive **inappropriate** treatment³

Resulting in higher mortality rates and prolonged hospital stays^{3,4}



FAST AST FOR BLOODSTREAM INFECTIONS

Empower clinicians to optimize treatment within hours not days¹⁰

- Results directly from positive blood cultures
- Deliver first AST results as early as **3 hours**,¹¹ with an average time-to-result of **5.5-6 hours**^{11,12}



ACTIONABLE RESULTS

Deliver reliable phenotypic results clinicians can trust¹¹

- Broad antimicrobial coverage** for gram-negative BSIs supports both **de-escalation and escalation strategies**
- Real-time MIC and categorical results** provide precise guidance for targeted treatment¹³



INTEGRATED & FLEXIBLE SOLUTION

Drive efficiency and maximize clinical value

- Seamless connectivity** with the bioMérieux Sepsis Solution, including the BIOFIRE® Blood Culture Identification 2 Panel
- Easily integrated into your laboratory workflow

OPTIMIZE RESOURCE UTILIZATION AND IMPLEMENTATION

MONITOR LAB KPIS AND EPIDEMIOLOGY TRENDS WITH MAESTRIA™

Simple automated reports to support BSI management and surveillance

KPIs Percentage: 40%		All Institutions											
		BSI	Gram +	Gram -	Enterobacteriaceae	Enterococci	Staphylococcus	Streptococcus	Acinetobacter	Pseudomonas	Legionella	Chlamydia	Other
Carbapenem	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Carbapenem	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Enterobacteriaceae	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Enterobacteriaceae	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Staphylococcus	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Staphylococcus	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Streptococcus	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Streptococcus	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Acinetobacter	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Acinetobacter	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Pseudomonas	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Pseudomonas	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Legionella	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Legionella	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Chlamydia	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Chlamydia	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100
Other	Total AST	100	100	100	100	100	100	100	100	100	100	100	100
Other	Time to AST	100	100	100	100	100	100	100	100	100	100	100	100

MAXIMIZE LAB PERFORMANCE AND ADVANCE AMS PROGRAMS

Our expert lab consultancy team is backed by over 35 years of leadership in automated AST.

- Instrument Service Contracts:** Maximize your instrument uptime
- Training Verification & Continued Education:** Streamline your lab activities
- Operational Services:** Access reliable and efficient logistics to support laboratory business continuity
- Lab Consultancy & Change Management Services:** Optimize laboratory process for maximum efficiency and faster time to reported result



FAST AST IMPROVES OUTCOMES AND EFFICIENCY



SHORTEN LENGTH OF STAY UP TO 2 DAYS⁵



IMPROVE ECONOMIC IMPACT
save €1022 - €3711 per patient⁶⁻⁸



OPTIMIZED PATIENT OUTCOMES
12h+ delays* in appropriate therapy increases mortality⁹
*From time of blood collection


EASILY SCALABLE TO MEET YOUR LAB'S NEEDS

*Based on average time to result of 5.5-6 hrs
**Image shows 6 modules

1 Module
4 Samples/shift



2 Modules
8 Samples/shift



3 Modules
12 Samples/shift




Up to 8 Modules*
32 Samples/shift**



INNOVATING MICROBIOLOGY TO SUPPORT AMS

VITEK REVEAL drives same-day* antibiotic adaptation for 48% of the patients¹³



- De-escalation
- Escalation
- Same Spectrum

* Same-day from positive blood culture


“The shorter time to results and turnaround time provided by the VITEK REVEAL system could enable clinicians to make timely adjustments to antimicrobial therapy, improving patient outcomes, and reducing the risk of healthcare-associated infections.” ¹⁰

INNOVATING MICROBIOLOGY FOR BETTER PATIENT CARE

For over 60 years we have been pushing the limits of technology to improve patient care. Count on VITEK® SOLUTIONS to address all your ID & AST needs from routine to critical patient challenges.

	VITEK REVEAL 1 MODULE	VITEK REVEAL SEALER
DIMENSIONS	≤ 44 cm (17.3 in) W ≤ 21 cm (8.3 in) H ≤ 72 cm (28.3 in) D	≤ 26 cm (10.2 in) W ≤ 45 cm (17.7 in) H ≤ 58 cm (28.8 in) D
REAR CLEARANCE	13 cm (5.1 in)	12.7 cm (5 in)
FRONT CLEARANCE	39 cm (15.4 in)	21 cm (8.3 in)
SIDE CLEARANCE	13 cm (5.1 in)	13 cm (5.1 in)
WEIGHT	35 kg (77 lb)	35 kg (77 lb)
CAPACITY	1 Module: 4 Samples/shift	

OPTIMIZE DIAGNOSTICS. MANAGE SEPSIS. WITH OUR FAST, INTEGRATED SOLUTION.



REFERENCES:

1. Rhee et al. JAMA Netw Open. 2024.
2. Shappell et al. Clin Infect Dis. 2025.
3. Kadri et al. Lancet Infect Dis. 2021.
4. Battle et al. J Antimicrob Chemother. 2017.
5. Walsh et al. Infection. 2021.
6. Bains et al. Anaesth Surg Open Access J. 2020.
7. Wilke et al. GMS Infect Dis. 2020.
8. Doern et al. J Clin Microbiol. 1994.
9. Van Heuverswyn et al. Clin Infect Dis. 2023.
10. Yuceel-Timur et al. J Antimicrob Chemother. 2024.
11. bioMérieux. BMX. 1.129899 Clinical trial summary report. [Proprietary document on file].
12. Rottman et al. P0733. ECCMID. 2022.
13. Tazi et al. JNI. 2023.

07-25 / BMX 1.162300 / 9328863 002 / GB / B2 / Document and/or picture not legally binding. Modifications by bioMérieux can be made without prior notice / BIOFIRE, VITEK, and VITEK REVEAL are used, pending and/or registered trademarks belonging to bioMérieux, or one of its subsidiaries, or one of its companies. / Any other name or trademark is the property of its respective owner. / bioMérieux S.A. RCS Lyon 673 620 399 / Photos bioMérieux / Printed in France / RCS Lyon B 398 160